Breaking News Bar

Business News and Information

Edge Therapeutics Reports Second Quarter 2018 Financial Results


Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced financial results for the quarter ended June 30, 2018.

Second Quarter Financial Results

Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2018 were $46.0 million, compared with $88.1 million as of December 31, 2017. In June 2018, Edge paid down its entire outstanding debt under the Amended Loan Agreement entered into August 2016 with Hercules Capital, Inc. In the second quarter, Edge substantially reduced its scope of operations, including the size of its workforce, in order to preserve its cash resources.

Operating Expenses:  Research and development (R&D) expenses were $2.5 million in the second quarter of 2018, compared to $9.0 million in the second quarter of 2017. The decrease in R&D expense was primarily due to a decrease in external expenses related to the previously announced discontinuance of the NEWTON 2 clinical study. General and administrative (G&A) expenses were $3.3 million for the three months ended June 30, 2018, compared to $4.2 million in the comparable period in 2017. The decrease in G&A expense was largely due to decreases in legal fees, professional fees, marketing costs and personnel costs. In the second quarter of 2018, Edge recorded a restructuring charge of $6.6 million, which consisted primarily of severance expense associated with the previously announced reduction in workforce and financial advisor fees related to the ongoing exploration of strategic alternatives.

Net Loss: Net loss for the second quarter ended June 30, 2018 was $12.7 million, including the $6.6 million restructuring charge. Net loss in the second quarter of 2017 was $13.5 million.

Review of Strategic Alternatives

On April 30, 2018, Edge announced that its Board of Directors is conducting a comprehensive review of strategic alternatives focused on maximizing stockholder value. Edge has retained Piper Jaffray & Co. to act as its financial advisor to assist with this review process. Potential strategic alternatives that may be explored or evaluated as part of this review include, but are not limited to, an acquisition, merger, business combination or other strategic transaction involving Edge.

There is no defined timeline for completion of the review process. There is no assurance that this review will result in Edge pursuing any transaction or that a transaction, if pursued, will be completed. Edge does not intend to discuss or disclose further developments regarding the strategic review process unless and until its Board of Directors has approved a specific action or otherwise determined that further disclosure is appropriate or required by law.

About Edge Therapeutics, Inc.
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that seeks to discover, develop and commercialize novel therapies capable of transforming treatment paradigms for the management of serious medical conditions. For additional information about Edge, please visit

Forward-Looking Statements
This press release and any statements of representatives of Edge Therapeutics, Inc. related thereto that are not historical in nature contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, without limitation, statements with respect to Edge’s plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," “seeks,” "intends," "plans," "potential" or similar expressions, including statements with respect to the potential effects of its products and plans to assess and undertake next steps for the company. These statements are based upon the current beliefs and expectations of Edge’s management and are subject to significant risks and uncertainties. Actual results may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various risk factors (many of which are beyond Edge's control) as described under the heading "Risk Factors" in Edge’s filings with the United States Securities and Exchange Commission.

Statements of Operations and Comprehensive Loss

 Three Months Ended June 30, Six Months Ended June 30,
 2018  2017  2018  2017 
Operating expenses:       
Research and development expenses$2,523,796  $8,975,304  $15,265,881  $16,564,800 
General and administrative expenses 3,335,039   4,173,384   8,016,555   8,375,226 
Restructuring expenses 6,646,242   -   6,646,242   - 
Impairment charges -   -   2,672,581   - 
Total operating expenses 12,505,077   13,148,688   32,601,259   24,940,026 
Loss from operations (12,505,077)  (13,148,688)  (32,601,259)  (24,940,026)
Other income (expense):           
Interest income 262,140   168,974   508,779   265,233 
Interest expense (434,695)  (524,768)  (1,425,255)  (999,909)
Net loss and comprehensive loss (12,677,632)  (13,504,482)  (33,517,735)  (25,674,702)
Loss per share basic and diluted$(0.41) $(0.44) $(1.08) $(0.86)
Weighted average common shares outstanding basic and diluted 31,298,429   30,403,419   31,133,070   29,704,898 

Balance Sheets

 June 30, 2018 December 31, 2017
Current assets:   
Cash and cash equivalents$45,978,737  $88,067,647 
Prepaid expenses and other current assets 580,279   986,680 
Total current assets 46,559,016   89,054,327 
Property and equipment, net 510,463   3,423,880 
Other assets 142,870   142,870 
Total assets$47,212,349  $92,621,077 
Current liabilities:     
Accounts payable$1,723,204  $4,369,133 
Accrued expenses 6,024,527   5,422,205 
Restructuring reserve 6,121,781   - 
Short term debt -   3,075,421 
Total current liabilities 13,869,512   12,866,759 
Noncurrent liability:     
Long term debt -   17,382,907 
Preferred stock, 5,000,000 shares authorized at June 30, 2018 and December 31, 2017, 0 outstanding -   - 
Common stock, $0.00033 par value, 75,000,000 shares authorized at June 30, 2018 and December 31, 2017, 31,328,128 shares and 30,869,205 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively 10,551   10,400 
Additional paid-in capital 218,798,380   214,309,370 
Accumulated deficit (185,466,094)  (151,948,359)
Total stockholders' equity 33,342,837   62,371,411 
Total liabilities and stockholders' equity$47,212,349  $92,621,077 

Investor and Media Contact:
Gregory Gin
Edge Therapeutics, Inc.
Tel: 1-800-208-EDGE (3343)

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear